More drug companies are disclosing the potential for clinical trial delays and drug shortages if the US government blacklists a family of WuXi companies used across the biopharma industry.
The disclosures come from companies large and small, including Merck, Cabaletta Bio and Kyverna Therapeutics. Through securities filings, Endpoints News identified nearly three dozen companies that rely on WuXi and have flagged the risk of a crackdown. The tally is more than double since March 13, when Endpoints first compiled a list of potentially affected companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.